Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis

Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis

Objective The present study aimed to provide a comprehensive evaluation of the postmarketing safety of belimumab based on the Food and Drug Administration Adverse Event Reporting System (FAERS) database.Methods Adverse event (AE) reports in the FAERS database from January 2021 to December 2023 were...

Full description

Saved in:

Bibliographic Details
Main Authors:	Huqun Li, Wenlong Xie, Chongshu Wang, Cuilian Guo
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-01-01
Series:	Lupus Science and Medicine
Online Access:	https://lupus.bmj.com/content/12/1/e001400.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system
by: Wei Mao, et al.
Published: (2025-01-01)

Safety evaluation of medroxyprogesterone acetate: a pharmacovigilance analysis using FDA adverse event reporting system data
by: Luyang Su, et al.
Published: (2024-12-01)

Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
by: Ximu Sun, et al.
Published: (2025-02-01)

Association of expedited review programmes with postmarketing safety events of new drugs approved by the US food and drug administration between 2007 and 2017
by: Bao Liu, et al.
Published: (2022-07-01)

Safety profiles of sevoflurane in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database
by: Chuang Yang, et al.
Published: (2025-02-01)

Pharmacovigilance in veterinary profession
by: Fatih Doğan

The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yue Zhou, et al.
Published: (2025-01-01)

Memory B cells and their transcriptomic profiles associated with belimumab resistance in systemic lupus erythematosus in the maintenance phase
by: Takeshi Iwasaki, et al.
Published: (2025-02-01)

Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study
by: Fei Han, et al.
Published: (2025-01-01)

Real-world effectiveness of intravenous belimumab in adults with systemic lupus erythematosus: results of the observational OBSErve study in the Russian Federation
by: Alexander Mikhailovich Lila, et al.
Published: (2025-01-01)

A study on the pharmacovigilance of various SGLT-2 inhibitors
by: Yanwen Dong, et al.
Published: (2025-01-01)

Pharmacovigilance imbalance analysis of VEGFR-TKI-related taste and smell disorders
by: Zhong-hua Fu, et al.
Published: (2025-01-01)

Typical use effectiveness of Natural Cycles: postmarket surveillance study investigating the impact of previous contraceptive choice on the risk of unintended pregnancy
by: Simon Rowland, et al.
Published: (2019-03-01)

Brodalumab: Six-Year US Pharmacovigilance Report
by: Mark G. Lebwohl, et al.
Published: (2024-11-01)

Real-Time Pharmacovigilance: Transforming Population-Based Monitoring of Post-Approval Vaccine Safety Through Rapid Cycle Analysis (RCA)—A Review of the Published Literature
by: Sampada Gandhi, et al.
Published: (2025-01-01)

Real world pharmacovigilance assessment of drug related macular degeneration risks
by: Xiaodong Chen, et al.
Published: (2025-01-01)

Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
by: Hui Chen
Published: (2025-01-01)

Intensive pharmacovigilance of Heberprot-P® in patients with diabetic foot ulcer
by: Annavely González Ocaña, et al.
Published: (2024-09-01)

Pharmacovigilance of carbamazepine at the Marta Abreu Polyclinic. Santa Clara, 2022
by: Adrián Ruíz López
Published: (2023-02-01)

Comparative Analysis of Adverse Drug Reactions Associated with Fluoroquinolones and Other Antibiotics: A Retrospective Pharmacovigilance Study
by: Alshareef H, et al.
Published: (2025-02-01)

Automatic tool for the reconciliation of serious adverse events for pharmacovigilance: design and implementation of Reconciliaid
by: Sara Contu, et al.
Published: (2025-01-01)

Phase 4 Pharmacovigilance Trial of Paromomycin Injection for the Treatment of Visceral Leishmaniasis in India
by: Prabhat K. Sinha, et al.
Published: (2011-01-01)

Beyond boundaries: Charting the frontier of healthcare with big data and ai advancements in pharmacovigilance
by: Arohi Agarwal, et al.
Published: (2025-03-01)

Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database
by: Bu-kun Zhu, et al.
Published: (2025-02-01)

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)
by: Ning Wang, et al.
Published: (2024-12-01)

A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system
by: Ke He, et al.
Published: (2025-01-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

Linear IgA bullous dermatosis secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system
by: Yixuan Yang, et al.
Published: (2025-01-01)

Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system
by: Jingrong Yang, et al.
Published: (2025-01-01)

High-risk adverse events in two types of single inhaler triple-therapy: a pharmacovigilance study based on the FAERS database
by: Zhishen Ruan, et al.
Published: (2025-01-01)

Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database
by: Wenchao Lu, et al.
Published: (2025-01-01)

Drug-induced urinary retention: a real-world pharmacovigilance study using FDA and Canada vigilance databases
by: Xianyu Dai, et al.
Published: (2025-01-01)

Systemic adverse drug events to topical prostaglandin analogs for treating glaucoma: a retrospective focused pharmacovigilance study
by: Kannan Sridharan
Published: (2024-12-01)

Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS)
by: Hui Gao, et al.
Published: (2025-01-01)

A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases
by: Siyu Lou, et al.
Published: (2025-01-01)

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
by: Jing Zhang, et al.
Published: (2025-02-01)

Drug-induced dementia: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
by: Lisi Xu, et al.
Published: (2025-01-01)

Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
by: Zhaohui Li, et al.
Published: (2024-11-01)

A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database
by: Yalan Tian, et al.
Published: (2025-01-01)

Drug-induced heart failure: a real-world pharmacovigilance study using the FDA adverse event reporting system database
by: Youqi Huang, et al.
Published: (2025-01-01)